These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 28964941)

  • 1. Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals.
    Herr A; Suppliet M
    J Health Econ; 2017 Dec; 56():19-29. PubMed ID: 28964941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reference pricing with endogenous generic entry.
    Brekke KR; Canta C; Straume OR
    J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can income-based co-payment rates improve disparity? The case of the choice between brand-name and generic drugs.
    Ito Y; Hara K; Yoo BK; Tomio J; Kobayashi Y
    BMC Health Serv Res; 2019 Nov; 19(1):780. PubMed ID: 31675967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of pharmaceutical prices: evidence from a reference price reform in Denmark.
    Kaiser U; Mendez SJ; Rønde T; Ullrich H
    J Health Econ; 2014 Jul; 36():174-87. PubMed ID: 24879578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
    Heo JH; Rascati KL; Lee EK
    Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.
    Mendoza RL
    J Med Econ; 2020 Sep; 23(9):915-922. PubMed ID: 32432950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More cost-sharing, less cost? Evidence on reference price drugs.
    Herr A; Stühmeier T; Wenzel T
    Health Econ; 2023 Feb; 32(2):413-435. PubMed ID: 36415146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
    Rosenberg ME; Rosenberg SP
    JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
    Rome BN; Feldman WB; Desai RJ; Kesselheim AS
    JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the demand for prescription drugs: heterogeneity in price responses.
    Skipper N
    Health Econ; 2013 Jul; 22(7):857-69. PubMed ID: 22899231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical.
    Kong Y
    Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, and Total Spending for Diagnostic Tests.
    Robinson JC; Whaley C; Brown TT
    JAMA Intern Med; 2016 Sep; 176(9):1353-9. PubMed ID: 27454826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pricing dynamics of anti-seizure medications in the U.S.
    Javarayee P; Mtchedlidze T; Snell W; Mahesha V; Meylor J; Shahrukh S; Pollock S; Sah J; Dong Y; Patel H
    Seizure; 2024 Nov; 122():26-33. PubMed ID: 39306895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indication-wide drug pricing: Insights from the pharma market.
    Siegmeier F; Büssgen M
    J Pharm Policy Pract; 2022 Aug; 15(1):53. PubMed ID: 36038951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment.
    Connolly MP; Griesinger G; Ledger W; Postma MJ
    Hum Reprod; 2009 Nov; 24(11):2796-800. PubMed ID: 19625316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad.
    Mattingly TJ; Seo D; Ostrovsky AM; Vanness DJ; Conti RM
    Res Social Adm Pharm; 2021 Aug; 17(8):1489-1495. PubMed ID: 33221266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discounting of medicines in Australian community pharmacies.
    Thai LP; Vitry AI; Moss JR
    Aust Health Rev; 2014 Nov; 38(5):517-22. PubMed ID: 25099433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.